Filing summary
Entity and period: This is Schweitzer-Mauduit International, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014. The supplied metadata names Mativ Holdings, Inc.; that is not the registrant named in this 2014 filing.
Business context and reporting period
SWM produced specialty papers, reconstituted tobacco products, and filtration materials. Its reportable segments were Paper, Reconstituted Tobacco, and Filtration. Filtration reflects the December 2013 DelStar acquisition; the filing says the acquisition broadened the company’s presence in advanced materials and filtration. The quarter’s results are not necessarily indicative of full-year results.
Financial results and liquidity
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Net sales | $204.7 million | $194.5 million |
| Gross profit / margin | $57.6 million / 28.1% | $62.7 million / 32.2% |
| Operating profit / margin | $33.1 million / 16.2% | $41.7 million / 21.4% |
| Net income | $23.2 million | $30.1 million |
| Diluted EPS | $0.75 | $0.96 |
| Cash provided by operations | $18.3 million | $41.3 million |
Interest expense rose to $1.5 million from $0.7 million, primarily reflecting higher acquisition-related debt. The effective tax rate was 30.2%, versus 29.3%. Comprehensive income was $26.6 million, compared with $21.1 million, as other comprehensive income improved despite lower net income.
At March 31, cash and cash equivalents were $277.9 million, including $277.4 million held by foreign subsidiaries. Total debt was $447.6 million, versus $385.4 million at year-end 2013; long-term debt was $439.4 million. The total debt-to-capital ratio increased to 46.0% from 40.7%. Credit Agreement availability was $73.6 million, with another $40.6 million available under bank overdraft facilities and lines of credit. The company reported compliance with its debt covenants.
Operating cash flow fell by $23.0 million year over year, driven mainly by lower earnings and a $19.7 million working-capital cash use, versus $3.4 million in the prior-year quarter. Investing used $11.6 million, including $8.1 million of capital spending. Financing used $0.4 million: $52.3 million of share repurchases and $11.1 million of dividends were largely offset by net borrowing proceeds. Capital spending for 2014 was projected at approximately $30 million.
Material changes versus the prior-year quarter
- Sales increased 5.2%, mainly because DelStar contributed $31.7 million in Filtration sales. This was partly offset by a $22.9 million combined adverse impact from volume, product mix, and selling prices, particularly in Reconstituted Tobacco, and by lower sales in Paper.
- Gross profit declined $5.1 million. Management cited lower volumes and selling prices, unfavorable mix, increased manufacturing costs, and energy and labor inflation; DelStar contributed $5.1 million of gross profit, partly offsetting those pressures.
- Operating profit declined $8.6 million, with lower results in Paper and Reconstituted Tobacco and higher unallocated expenses. General expense rose by $4.2 million, including acquisition-related and growth-related costs.
- Reconstituted Tobacco sales fell 20.5% to $44.2 million, and segment operating profit declined to $16.2 million from $21.4 million. Paper sales fell 7.3% to $128.8 million. Filtration reported $31.7 million in sales and $0.4 million in operating profit.
- Cash and cash equivalents increased by $5.9 million during the quarter, while debt increased by $62.2 million from year-end. The company repurchased 1,160,811 shares for $52.3 million; its then-authorized $50 million repurchase program was fully used by March 31.
Outlook, commentary, risks, and unusual items
- Management expected Reconstituted Tobacco volumes and operating profit to decline meaningfully in 2014 versus 2013. It was evaluating the implications for French operations and a suspended Philippines site and had begun offering a voluntary departure and early-retirement program in France; participation and cost were not finalized.
- The CTS China joint venture facility was expected to begin operating around mid-2014, reach full capacity by 2016, incur additional start-up expense in 2014, and achieve profitable operations in 2015. These are management expectations, not reported outcomes.
- Management viewed prospective lower-ignition-propensity cigarette regulations, including a targeted mid-2015 implementation in South Korea, as a potential source of demand. Timing and implementation remained uncertain. It also cited potential reconstituted-tobacco demand from proposed tar limits in China and expected filtration growth, particularly in water filtration.
- Key stated risks included cigarette-consumption declines, customer demand and pricing, competition, commodity and energy costs, inflation, currency and interest-rate movements, regulation, acquisitions and integration, joint-venture risks, and legal proceedings.
- Brazilian tax disputes included approximately $40 million of raw-material ICMS assessments, of which approximately $18 million was covered by an indemnification, and approximately $20 million of electricity-related assessments. SWM-B was contesting the assessments and management expected favorable resolution; no liability was recorded.
- DelStar purchase accounting remained provisional. The quarter included a $3.3 million inventory fair-value revaluation adjustment in Filtration gross profit and $0.4 million of acquisition-related expense. Management said the acquisition’s final appraisals were incomplete.
- Discontinued operations from the previously sold Indonesia mill and closed Philippines mill had no reported loss in Q1 2014, versus a $0.6 million loss in Q1 2013.
Important facts for investors to verify
- Confirm the intended issuer: this filing is for Schweitzer-Mauduit International, Inc., not Mativ Holdings, Inc.
- Track whether the expected declines in Reconstituted Tobacco and the French voluntary departure program affect subsequent results and costs.
- Review DelStar’s operating contribution, integration progress, and completion of provisional acquisition valuations, including the inventory step-up effect.
- Monitor debt, covenant headroom, and the concentration of cash in foreign subsidiaries alongside working-capital cash flow.
- Follow the Brazilian tax proceedings and indemnification coverage; the disclosed assessments were not accrued as liabilities.
- Compare management’s expectations for CTS start-up, profitability, LIP regulation, and filtration growth with later disclosures and results.